Navigation Links
BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
Date:4/26/2008

DE (n=1) and 12 percent of

patients receiving adefovir (n=5) experienced a serious adverse event.

-- No deaths were observed in either treatment group.

-- No patients in the BARACLUDE arm and one patient in the adefovir arm

experienced an ALT flare (defined as ALT greater than two times

baseline and greater than 10 times the upper limit of normal).

About the Study

The E.A.R.L.Y. study (ETV-079) is a randomized, open-label, comparative viral kinetics study of antiviral-naive chronic HBeAg-positive patients evaluating antiviral activity as measured by mean reduction in viral load, or levels of hepatitis B virus (HBV DNA) in the blood. HBeAg or e-antigen, is a viral protein associated with hepatitis B infections, and is found in the blood only when there is virus present.

The primary endpoint for the study was mean reduction in HBV DNA levels at week 12. The secondary endpoints included the mean change in viral load from baseline through week 96, the proportion of patients in each treatment group who achieved ALT normalization, HBeAg loss and HBe seroconversion, and safety.

Sixty-nine patients were randomized in the study and of these, 65 completed the first 12 weeks. Patients in this study received either 0.5 mg of BARACLUDE(R) (entecavir) once daily (n=33) or 10 mg of adefovir once daily (n=32) for a minimum of 52 weeks. Patients in the BARACLUDE treatment group had a mean baseline viral load of 10.26 log(10) copies/mL. Patients in the adefovir treatment group had a mean baseline viral load of 9.88 log(10) copies/mL.

According to study protocol, patients who achieved a treatment response at 52 weeks discontinued treatment and entered a follow-up monitoring phase. Three BARACLUDE-treated patients and four adefovir-treated patients met this criterion and entered the follow-up monitoring phase lasting up to 48 weeks. Patients who did not achieve a treatment response at 52 weeks continued on study
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Many Heart Attack Patients Dont Get Best Emergency Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Decision Resources, one of the world,s ... and healthcare issues, finds that over 70 percent ... high need for diabetes drugs with novel mechanisms ... is a high need for additional DPP-IV inhibitors. ... excellent glucose lowering ability and physicians in particular ...
(Date:12/16/2009)... Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: ... 2010 the U.S. Food and Drug Administration,s ... the New Drug Application (NDA) for pixantrone ... lymphoma (NHL). ODAC is an independent panel ... efficacy and safety of marketed and investigational ...
(Date:12/16/2009)... Ohio, Dec. 16 HDT Engineered Technologies ... generation technologies and a principal subcontractor for the ... led development of new anthropromorphic arm technology that ... prosthetic arm and hand, including a sense of ... Advanced Research Projects Agency (DARPA) Revolutionizing Prosthetics 2009 ...
Breaking Medicine Technology:Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 2Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 3Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 2Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 3Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 4HDT Develops Robotic Arm Technology for DARPA's Revolutionizing Prosthetics 2009 Program 2Premiere Fibers Unveils New Logo Names for Innovative Brands 49074 1Premiere Fibers Unveils New Logo Names for Innovative Brands 49074 2Wyeth Announces Holder Right to Surrender Convertible Debentures 12653 1Wyeth Announces Holder Right to Surrender Convertible Debentures 12653 2Wyeth Announces Holder Right to Surrender Convertible Debentures 12653 3Wyeth Announces Holder Right to Surrender Convertible Debentures 12653 4Torn Surgical Gloves Put Patients at Risk for Infection 49069 1Torn Surgical Gloves Put Patients at Risk for Infection 49069 2
... ... Treatment HUNTINGTON BEACH, Calif., and AMSTERDAM, ... cancer diagnostics,today announced the launch of TargetPrint(R), a new ... expression levels of,the estrogen receptor (ER), progesterone receptor (PR) ...
... and Education Foundation,s Within Our Reach Campaign Yields Significant ... ... 3 For the first time during its,unprecedented initiative to ... Research and Education Foundation is,releasing new information acquired from research ...
Other Medicine Technology:Agendia Launches TargetPrint(R) for Breast Cancer Patients 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 3
(Date:12/17/2009)... TROY, Mich., Dec. 17 CareTech Solutions ( ... and services provider for hospitals and health systems, was ... segment, in the 2009 Top 20 Best in ... report ranks the performance of vendors in ... and many others. ,, CareTech,s overall performance ...
(Date:12/17/2009)... one of the nation,s largest non-profit providers of skin, ... procedures and the world,s largest processor of live cellular ... selected as a finalist in the 2010 Colorado Ethics ... category honoring non-profits. This is the second year in ... finalist by the annual awards program, now in its ...
(Date:12/17/2009)... (December 17, 2009) Researchers from the La ... at several of the world,s most dangerous infectious diseases ... five-year, $18.8 million federally-funded set of projects seeking to ... , The Institute received four project awards totaling ... Infectious Diseases (NIAID), part of the National Institutes of ...
(Date:12/17/2009)... Personal Stories of Inspiration on How Exercise Has Helped, Healed, and ... ... 2009 -- The International Health, Racquet & Sportsclub Association (IHRSA) announced ... it is urging Americans of all ages and abilities to make ... a culture of movement in America wherein regular daily exercise is ...
(Date:12/17/2009)... in Human Resource Development Degree Online , ... ... enrollment has begun for Villanova’s newly online HR master’s ... busy schedules can’t accommodate a campus-based program. With the university’s ... March 2010, location is no longer a barrier to the ...
Breaking Medicine News(10 mins):Health News:CareTech Solutions Named 2009 'Best in KLAS' for Extensive Information Technology Outsourcing for the Second Consecutive Year 2Health News:CareTech Solutions Named 2009 'Best in KLAS' for Extensive Information Technology Outsourcing for the Second Consecutive Year 3Health News:AlloSource Recognized for Exemplifying Ethics Amongst Colorado Non-Profits 2Health News:AlloSource Recognized for Exemplifying Ethics Amongst Colorado Non-Profits 3Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 2Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 3Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 4Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 5Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 2Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 3Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 4Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 5Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 3
... formal services will be held during The Compassionate Friends 12th ... in memory of all children who have died at any ... largest mass candle Lighting this year,s observance will be held ... around the world creating a 24-hour wave of light. ...
... Expert Tips and Tricks To Help You Through Tumultuous Times and ... Nov. 25 Equinox is well aware that these days, stress ... and it,s quite possible that all of this could be making ... in 50-80% of all diseases and may be responsible for up ...
... M. Parker, board certified plastic surgeon in New Jersey, tummy tuck ... Dr. Parker is proud to be among the pioneers in the ... traditional with the advanced for a beautiful, youthful-appearing abdomen. , ... ...
... Whole Life Success Recovery Program™ provides a complete home business to ... become fiscally responsible and productive members of society. , ... ... alcoholism recovery community, Alcohol Support Group.com, http://www.alcoholsupportgroup.com/ , is ...
... leading provider of Healthcare Solutions since 1977, announced the release of ... ADS MedicsDocAssistant ™Suite. ADS,s Suite solution has a product for ... suite of products on the market today. , ... ...
... N.J. and MONTVALE, N.J., Nov. 25 Roche and ... that the two companies have signed a definitive merger ... of Memory Pharmaceuticals in an all-cash transaction for an ... , Memory Pharmaceuticals develops ...
Other Medicine News:Health News:Compassionate Friends Worldwide Candle Lighting December 14 Unites Families Mourning Children 2Health News:Compassionate Friends Worldwide Candle Lighting December 14 Unites Families Mourning Children 3Health News:Mind (Body and Spirit) Over Madness 2Health News:Mind (Body and Spirit) Over Madness 3Health News:Dr. Paul M. Parker Is Pioneering New Advanced Lipoabdominoplasty Instead of Traditional Tummy Tuck in New Jersey 2Health News:Dr. Paul M. Parker Is Pioneering New Advanced Lipoabdominoplasty Instead of Traditional Tummy Tuck in New Jersey 3Health News:Dr. Paul M. Parker Is Pioneering New Advanced Lipoabdominoplasty Instead of Traditional Tummy Tuck in New Jersey 4Health News:Free Home Business to Individuals Recovering from Alcoholism Provided by AlcoholSupportGroup.com 2Health News:ADS Announces EMR Solution for Every Practice and Budget 2Health News:ADS Announces EMR Solution for Every Practice and Budget 3Health News:Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals 2Health News:Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals 3Health News:Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: